Jan 29 – Jan 31, 2019
Boston, MA

2019 Confirmed Speakers

Expand/Collapse

Giustino Di Pretoro
Associate Director – Continuous Manufacturing
Johnson & Johnson

Giustino Di Pretoro is an Associate Director at Janssen Pharmaceutica, a Johnson & Johnson Company. Dr. Di Pretoro is a subject matter expert and drug product development lead for continuous manufacturing, and coordinator for a series of academic collaborations within the field. Before joining Johnson & Johnson, Giustino was Team Leader and Principal Scientist at Novo Nordisk AS (DK), where he was heading a formulation team focusing on oral delivery of biomolecules, and prior as R&D and Business Development Manager for a Swiss CMO, focussing on novel technologies for particle size reduction and solubility improvement of class II BCS drugs. Giustino’s main area of research is oral solid formulation of small- and bio-molecules, novel drug delivery systems and pharmaceutical development.   Giustino holds a Ph.D. in Pharmaceutical Technology and Msc. in Industrial Pharmacy, from the University of Milan (I). Within his Ph.D. he worked as Research Scientist at the University of Cambridge (UK) in the Chemical Engineering and Biotechnology department, and later as visiting postdoc in Pharmaceutical Technology at the University of Düsseldorf (DE).  

Day One

Wednesday January 31, 2018

09.30 | Panel Discussion: Establishing a Winning Business Case for Investment

Day Two

Thursday February 1, 2018

09.10 | Opening Address: Manufacturing the Future: The Journey from Batch to Continuous Manufacturing from an Industry Perspective

Neil Soice
Director, Pre-Pivotal Bioprocess Development
Amgen

Salvatore Mascia
Founder & CEO
Continuus Pharmaceuticals

Lawrence De Belder
Senior Principal Engineer, Continuous Manufacturing
Janssen

Narasimha Rao Nedunuri
Managing Director & CEO
CLONZ Biotech Pvt Ltd.

Robert Worsham
Director of Manufacturing Science & Technology
Insmed Inc.

Engin Ayturk
Senior Manager, Technical Development
Biogen

Engin Ayturk, is a Senior Manager at Biogen, leading the Cambridge Process Biochemistry (PBC) small and pilot scale purification development teams, and responsible for the development of purification processes for clinical and commercial biologics programs. Prior to Biogen, Engin was the Sr. R&D Manager at Pall Life Sciences, where he led the BioPharm Applications R&D Integrated Continuous BioProcessing team and the Filtration Groups for the development and commercialization of next generation novel bioprocess platforms and technologies In addition to his primary focus on product, process and technology development, characterization, scale-up and tech transfer, Dr. Ayturk brings a strong emphasis on process modeling, bioprocess economics and the development of process control strategies for various technologies and is well recognized for cross-functional team leadership, internal/external collaborations and partnerships management as has numerous business certifications on project and people management, agile product development and innovation coaching modules. Dr. Ayturk holds M.Sc. and Ph.D. degrees both in Chemical Engineering and previously worked as a Research Assistant Professor at Worcester Polytechnic Institute (WPI).

Day One

Wednesday January 31, 2018

14.30 | Progress & Challenges in Bridging the Gap – End-to-End Continuous Processing

Keith Selvitelli
Senior Scientist
Biogen

Bob Lenich
Life Science Business Director
Emerson Automation Solutions

Bob is a life-long learner who stays engaged in new technology and organizational trends in order to adapt them to solving operating issues across the process industries. He works with a wide variety of organizations to identify operational problems, evaluate how to make improvements, and then justify and sell the approach. Bob loves seeing the successful deployment of a solution and then sharing the benefits so that others can take advantage of the approach. Bob gets special gratification from seeing how those improvements help areas like Life Science manufacturing improve people’s lives. Bob currently is responsible for planning Emerson's strategy for growing our automation business in the Life Science industry globally.  He then collaboratively works across the various business units in Emerson to implement the strategy and build the business. Bob has a BS in Chemical Engineering from Rose Hulman Institute of Technology and an MBA from the University of Texas.

Day One

Wednesday January 31, 2018

16.15 | Planning Automation to Deliver Continuous Manufacturing Benefits

Senior Representative

Sartorius Stedim Biotech GmbH

Day One

Wednesday January 31, 2018

12.45 | Scalable Technologies for Process Intensification in the Factories of the Future

Lisa Graham
CEO & Founder
Alkemy Innovation

Dr. Graham is CEO and founder of Alkemy Innovation, Inc. She is a registered professional chemical engineer with 20 years technical and business experience and expertise in chemical engineering, data analytics, applied mathematics, business system planning, and process analytical technology applications. She is the author of 12 scientific papers and 25 professional presentations, with 2 patents. She is also actively involved in supporting higher education, specifically STEM education initiatives, and economic development at the State level, including serving as Chair of the Board for Oregon Tech and serving on the Oregon Governor’s STEM Investment Council.

Day One

Wednesday January 31, 2018

09.30 | Panel Discussion: Establishing a Winning Business Case for Investment

Gerard Gach
Chief Marketing Officer
LEWA Bioprocess Technologies

Gerard Gach is the Chief Marketing Officer (CMO) of LEWA-Nikkiso Bioprocess Technologies Group. He leads company in identifying growth segments within the life science space, directing the business strategy to support the commercial growth of LEWA-Nikkiso on a global basis. Previously Gerard was the Global Strategic Leader, Bioprocess Cell Culture of General Electric’s Health Care (GEHC) Life Science Division. At GEHC Gerard also served as Director of Product Management for Bioreactors, Disposables, and Membrane business where his team was responsible for developing and bringing to market an entirely new platform over 250 single use products while managing membrane based products for the GE business involved in bioprocess, protein science and lab products. He has previously served as Global Marketing Leader, for the Advanced Separations business of GE Water & Process centered on novel membrane and chemical separation technology. His employment history includes over 28 years in the filtration / separations industry with GE,  Osmonics, Koch Membrane Systems and Pall Corporation in capacities of R&D Supervisor, Sales and Sale Management and Business Development.

Day One

Wednesday January 31, 2018

14.15 | SPOTLIGHT: A Simple Design to a Flexible Multi-Column Chromatography Platform

Oleg Shinkazh
Founder & CEO
ChromaTan Corporation

Oleg Shinkazh is a founder of ChromaTan and inventor of “Countercurrent Tangential Chromatography.” He is a chemical and biotechnology engineer with 17 years of experience in R&D and technical support in the biotechnology industry, specializing in downstream processing/purification of human biologics. Oleg has extensive experience with all unit operations in the modern marketplace and has worked and collaborated with multiple industry leading bioprocess end-users and supplier companies.

Day One

Wednesday January 31, 2018

15.30 | Integrated End-To-End Continuous Bioprocessing – An Industry-Wide and US Government Sponsored Initiative for Steady-State Manufacturing of Biologics Using Continuous Countercurrent Tangential Chromatography (CCTC)